Skye Bioscience Inc
SKYE0.930USD
-0.070-6.99%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
28.82MMarket Cap
LossP/E TTM
More Details of Skye Bioscience Inc Company
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Skye Bioscience Inc Info
Ticker SymbolSKYE
Company nameSkye Bioscience Inc
IPO dateFeb 24, 2014
CEODhillon (Punit S)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 24
Address11250 El Camino Real, Suite 100
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18584100266
Websitehttps://skyebioscience.com/
Ticker SymbolSKYE
IPO dateFeb 24, 2014
CEODhillon (Punit S)
Company Executives of Skye Bioscience Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Punit S. Dhillon
Dr. Punit S. Dhillon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
170.32K
+1.59%
Mr. Christopher (Chris) Twitty, Ph.D.
Mr. Christopher (Chris) Twitty, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
81.24K
--
Mr. Tuan Tu Diep
Mr. Tuan Tu Diep
Chief Operating Officer
Chief Operating Officer
39.05K
+3.53%
Mr. Paul A. Grayson
Mr. Paul A. Grayson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Andrew J. (Andy) Schwab
Mr. Andrew J. (Andy) Schwab
Director
Director
--
--
Dr. Puneet S. Arora
Dr. Puneet S. Arora
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
--
--
Ms. Kaitlyn Arsenault, CPA
Ms. Kaitlyn Arsenault, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Deborah Charych, Ph.D.
Dr. Deborah Charych, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Punit S. Dhillon
Dr. Punit S. Dhillon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
170.32K
+1.59%
Mr. Christopher (Chris) Twitty, Ph.D.
Mr. Christopher (Chris) Twitty, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
81.24K
--
Mr. Tuan Tu Diep
Mr. Tuan Tu Diep
Chief Operating Officer
Chief Operating Officer
39.05K
+3.53%
Mr. Paul A. Grayson
Mr. Paul A. Grayson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Andrew J. (Andy) Schwab
Mr. Andrew J. (Andy) Schwab
Director
Director
--
--
Dr. Puneet S. Arora
Dr. Puneet S. Arora
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
5AM Ventures
30.20%
Versant Ventures
6.26%
Baker Bros. Advisors LP
4.53%
Schonfeld Strategic Advisors LLC
3.70%
The Vanguard Group, Inc.
2.75%
Other
52.55%
Shareholders
Shareholders
Proportion
5AM Ventures
30.20%
Versant Ventures
6.26%
Baker Bros. Advisors LP
4.53%
Schonfeld Strategic Advisors LLC
3.70%
The Vanguard Group, Inc.
2.75%
Other
52.55%
Shareholder Types
Shareholders
Proportion
Venture Capital
36.46%
Hedge Fund
12.90%
Investment Advisor
7.50%
Investment Advisor/Hedge Fund
5.68%
Individual Investor
1.52%
Research Firm
0.21%
Bank and Trust
0.17%
Other
35.57%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
154
20.48M
66.10%
-9.05M
2025Q2
148
24.31M
78.45%
-5.93M
2025Q1
146
25.43M
82.12%
-5.35M
2024Q4
134
25.96M
85.58%
-3.70M
2024Q3
124
26.72M
88.10%
+246.63K
2024Q2
93
25.14M
89.58%
+8.75M
2024Q1
21
18.17M
74.19%
+2.29M
2023Q4
17
9.21M
74.78%
+8.43M
2023Q3
14
7.46M
73.77%
+6.98M
2023Q2
11
717.54K
19.61%
+249.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
5AM Ventures
9.68M
31.24%
-231.41K
-2.33%
Aug 22, 2025
Versant Ventures
2.01M
6.48%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
1.45M
4.68%
--
--
Jun 30, 2025
Schonfeld Strategic Advisors LLC
1.10M
3.54%
-519.26K
-32.11%
Jun 30, 2025
The Vanguard Group, Inc.
837.96K
2.7%
-115.41K
-12.11%
Jun 30, 2025
Ensign Peak Advisors, Inc.
767.29K
2.48%
--
--
Jun 30, 2025
Driehaus Capital Management, LLC
620.39K
2%
--
--
Jun 30, 2025
Sphera Funds Management Ltd.
538.43K
1.74%
-937.92K
-63.53%
Jun 30, 2025
Alyeska Investment Group, L.P.
456.16K
1.47%
--
--
Jun 30, 2025
Millennium Management LLC
470.73K
1.52%
+470.73K
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Tema Heart & Health ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
AdvisorShares Pure Cannabis ETF
0%
Vanguard US Minimum Volatility ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Tema Heart & Health ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
AdvisorShares Pure Cannabis ETF
Proportion0%
Vanguard US Minimum Volatility ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Skye Bioscience Inc?
The top five shareholders of Skye Bioscience Inc are:
5AM Ventures holds 9.68M shares, accounting for 31.24% of the total shares.
Versant Ventures holds 2.01M shares, accounting for 6.48% of the total shares.
Baker Bros. Advisors LP holds 1.45M shares, accounting for 4.68% of the total shares.
Schonfeld Strategic Advisors LLC holds 1.10M shares, accounting for 3.54% of the total shares.
The Vanguard Group, Inc. holds 837.96K shares, accounting for 2.70% of the total shares.
5AM Ventures holds 9.68M shares, accounting for 31.24% of the total shares.
Versant Ventures holds 2.01M shares, accounting for 6.48% of the total shares.
Baker Bros. Advisors LP holds 1.45M shares, accounting for 4.68% of the total shares.
Schonfeld Strategic Advisors LLC holds 1.10M shares, accounting for 3.54% of the total shares.
The Vanguard Group, Inc. holds 837.96K shares, accounting for 2.70% of the total shares.
What are the top three shareholder types of Skye Bioscience Inc?
The top three shareholder types of Skye Bioscience Inc are:
5AM Ventures
Versant Ventures
Baker Bros. Advisors LP
5AM Ventures
Versant Ventures
Baker Bros. Advisors LP
How many institutions hold shares of Skye Bioscience Inc (SKYE)?
As of 2025Q3, 154 institutions hold shares of Skye Bioscience Inc, with a combined market value of approximately 20.48M, accounting for 66.10% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.35%.
What is the biggest source of revenue for Skye Bioscience Inc?
In --, the -- business generated the highest revenue for Skye Bioscience Inc, amounting to -- and accounting for --% of total revenue.
